Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapy treatments. Its pipeline includes soquelitinib (formerly CPI-818), ciforadenant, and mupadolimab. The company conducts clinical trials for these product candidates, leverages biomarker data to support clinical development, and has a collaboration with Angel Pharmaceuticals. Corvus has not yet commercialized any products.
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001104659-26-027047 | EDGAR | 80K words |
| 2025-03-25 | 2024-12-31 | 0001558370-25-003621 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001558370-24-003567 | EDGAR | — |
| 2023-03-28 | 2022-12-31 | 0001558370-23-004792 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001558370-22-003281 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001558370-21-003462 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001558370-20-002232 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001558370-19-001660 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001047469-18-001209 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001047469-17-001459 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-106259 | EDGAR | 56K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010755 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006966 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015306 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011076 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007093 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017981 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013914 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001558370-23-008503 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016233 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012619 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007374 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001104659-26-027390 | EDGAR | 21K words |
| 2026-03-12 | 0001171843-26-001526 | EDGAR | — |
| 2026-01-23 | 0001104659-26-005968 | EDGAR | — |
| 2026-01-20 | 0001104659-26-005035 | EDGAR | — |
| 2026-01-20 | 0001104659-26-004795 | EDGAR | — |
| 2025-11-04 | 0001171843-25-006973 | EDGAR | — |
| 2025-10-02 | 0001104659-25-096103 | EDGAR | — |
| 2025-08-07 | 0001171843-25-005180 | EDGAR | — |
| 2025-06-13 | 0001171843-25-003881 | EDGAR | — |
| 2025-06-04 | 0001171843-25-003661 | EDGAR | — |
189 total filings indexed. 157 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001626971 |
| Ticker | CRVS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.corvuspharma.com |
| Listed | 2016-03-23 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report